Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
RPRX's Cash to Debt is ranked higher than
97% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. RPRX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RPRX' s Cash to Debt Range Over the Past 10 Years
Min: 23  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.91
RPRX's Equity to Asset is ranked higher than
86% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RPRX: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
RPRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.09  Med: 0.92 Max: 0.99
Current: 0.91
0.09
0.99
Interest Coverage No Debt
RPRX's Interest Coverage is ranked higher than
95% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RPRX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RPRX' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -12.29
M-Score: -4.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -607360.00
RPRX's Operating margin (%) is ranked lower than
100% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. RPRX: -607360.00 )
Ranked among companies with meaningful Operating margin (%) only.
RPRX' s Operating margin (%) Range Over the Past 10 Years
Min: -624550  Med: -103172.66 Max: -908.49
Current: -607360
-624550
-908.49
Net-margin (%) -607360.00
RPRX's Net-margin (%) is ranked lower than
100% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. RPRX: -607360.00 )
Ranked among companies with meaningful Net-margin (%) only.
RPRX' s Net-margin (%) Range Over the Past 10 Years
Min: -624550  Med: -95297.66 Max: -908.49
Current: -607360
-624550
-908.49
ROE (%) -80.74
RPRX's ROE (%) is ranked lower than
77% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. RPRX: -80.74 )
Ranked among companies with meaningful ROE (%) only.
RPRX' s ROE (%) Range Over the Past 10 Years
Min: -336.72  Med: -129.11 Max: -55.84
Current: -80.74
-336.72
-55.84
ROA (%) -75.44
RPRX's ROA (%) is ranked lower than
81% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. RPRX: -75.44 )
Ranked among companies with meaningful ROA (%) only.
RPRX' s ROA (%) Range Over the Past 10 Years
Min: -237.27  Med: -105.43 Max: -52.9
Current: -75.44
-237.27
-52.9
ROC (Joel Greenblatt) (%) -125487.60
RPRX's ROC (Joel Greenblatt) (%) is ranked lower than
99% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. RPRX: -125487.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RPRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -136170  Med: -51810.91 Max: -24464.29
Current: -125487.6
-136170
-24464.29
EBITDA Growth (3Y)(%) 10.50
RPRX's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. RPRX: 10.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RPRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -51.7  Med: -2.15 Max: 68.7
Current: 10.5
-51.7
68.7
EPS Growth (3Y)(%) 10.00
RPRX's EPS Growth (3Y)(%) is ranked higher than
68% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. RPRX: 10.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RPRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.2  Med: 5.20 Max: 113.7
Current: 10
-59.2
113.7
» RPRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

RPRX Guru Trades in Q1 2015

Chuck Royce 191,000 sh (-23.90%)
» More
Q2 2015

RPRX Guru Trades in Q2 2015

Jim Simons 202,143 sh (New)
Chuck Royce 191,000 sh (unchged)
» More
Q3 2015

RPRX Guru Trades in Q3 2015

Chuck Royce 129,000 sh (-32.46%)
Jim Simons 44,900 sh (-77.79%)
» More
Q4 2015

RPRX Guru Trades in Q4 2015

Chuck Royce 129,000 sh (unchged)
Jim Simons 33,913 sh (-24.47%)
» More
» Details

Insider Trades

Latest Guru Trades with RPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.82
RPRX's P/B is ranked higher than
90% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.56 vs. RPRX: 0.82 )
Ranked among companies with meaningful P/B only.
RPRX' s P/B Range Over the Past 10 Years
Min: 0.7  Med: 7.66 Max: 85
Current: 0.82
0.7
85
P/S 3943.35
RPRX's P/S is ranked lower than
99.99% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. RPRX: 3943.35 )
Ranked among companies with meaningful P/S only.
RPRX' s P/S Range Over the Past 10 Years
Min: 0  Med: 246.67 Max: 4467.3
Current: 3943.35
0
4467.3
EV-to-EBIT 0.26
RPRX's EV-to-EBIT is ranked higher than
100% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 19.35 vs. RPRX: 0.26 )
Ranked among companies with meaningful EV-to-EBIT only.
RPRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.1  Med: -7.70 Max: 0.3
Current: 0.26
-31.1
0.3
EV-to-EBITDA 0.26
RPRX's EV-to-EBITDA is ranked higher than
100% of the 457 Companies
in the Global Biotechnology industry.

( Industry Median: 16.36 vs. RPRX: 0.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
RPRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.5  Med: -7.80 Max: 0.3
Current: 0.26
-31.5
0.3
Current Ratio 10.64
RPRX's Current Ratio is ranked higher than
76% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. RPRX: 10.64 )
Ranked among companies with meaningful Current Ratio only.
RPRX' s Current Ratio Range Over the Past 10 Years
Min: 0.23  Med: 9.30 Max: 66.45
Current: 10.64
0.23
66.45
Quick Ratio 10.64
RPRX's Quick Ratio is ranked higher than
77% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. RPRX: 10.64 )
Ranked among companies with meaningful Quick Ratio only.
RPRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.23  Med: 8.91 Max: 66.45
Current: 10.64
0.23
66.45

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.84
RPRX's Price/Net Cash is ranked higher than
98% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: 5.77 vs. RPRX: 0.84 )
Ranked among companies with meaningful Price/Net Cash only.
RPRX' s Price/Net Cash Range Over the Past 10 Years
Min: 0.45  Med: 5.20 Max: 84.15
Current: 0.84
0.45
84.15
Price/Net Current Asset Value 0.82
RPRX's Price/Net Current Asset Value is ranked higher than
98% of the 849 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. RPRX: 0.82 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RPRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.43  Med: 5.06 Max: 224.36
Current: 0.82
0.43
224.36
Price/Tangible Book 0.82
RPRX's Price/Tangible Book is ranked higher than
97% of the 1004 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. RPRX: 0.82 )
Ranked among companies with meaningful Price/Tangible Book only.
RPRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.42  Med: 4.94 Max: 151.37
Current: 0.82
0.42
151.37
Earnings Yield (Greenblatt) (%) 441.41
RPRX's Earnings Yield (Greenblatt) (%) is ranked higher than
100% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. RPRX: 441.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RPRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 291.6  Med: 464.50 Max: 41501.3
Current: 441.41
291.6
41501.3

More Statistics

Revenue(Mil) $0
EPS $ -1.25
Beta0.33
Short Percentage of Float4.25%
52-Week Range $0.80 - 10.05
Shares Outstanding(Mil)24.32

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 0 0 0 0
EPS($) -1.21 -0.95 -0.54 -0.91
EPS without NRI($) -1.21 -0.95 -0.54 -0.91

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ZONN.Germany,
Repros Therapeutics Inc was organized on August 20, 1987. The Company is a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's main product candidate, Androxal, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. It is developing Androxal for men of reproductive age with low testosterone levels. Androxal treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. The Company's second product candidate, Proellex for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. The Company recently completed a low dose study to demonstrate both safety and signals of efficacy in low oral doses of Proellex. The Company's research and development activities, preclinical studies and clinical trials, and the manufacturing, marketing and labeling of any products it may develop, are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries.
» More Articles for RPRX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 
Repros Therapeutics Inc. (RPRX) CEO Joseph Podolski buys 4,000 Shares Mar 05 2009 
Weekly CEO Buys Highlight: Medtox Scientific Inc., Provident Bankshares Corp., Escalade Inc., Repros Apr 25 2008 

More From Other Websites
Repros, FDA Meet to Discuss Issues of Enclomiphene's CRL Feb 09 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 08 2016
Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment... Feb 08 2016
Smart Money Highlights Oversold Stocks in Small Cap Biotechs Jan 19 2016
Repros Announces Court of Appeals' Affirmation of Summary Judgment in Favor of the Company Jan 11 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 11 2016
Repros Announces Court of Appeals’ Affirmation of Summary Judgment in Favor of the Company Jan 11 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 06 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 04 2016
Repros Updates Enclomiphene Program Jan 04 2016
Repros Provides Update on Proellex Program, Data by 3Q16 Dec 22 2015
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Dec 21 2015
Repros Updates Proellex® Program Dec 21 2015
Is Evolution Petroleum Corporation (EPM) Going to Burn These Hedge Funds? Dec 09 2015
REPROS THERAPEUTICS INC. Financials Dec 08 2015
The Zacks Analyst Blog Highlights: Repros Therapeutics, AbbVie, Amgen, XOMA and Gilead Dec 03 2015
Repros Hits 52-Week Low after Enclomiphene Receives CRL Dec 02 2015
Biotech Stock Roundup: Repros Tanks on CRL, AbbVie Multiple Myeloma Drug Approved Dec 02 2015
Repros (RPRX) Stock Plummets After FDA Rejects Hypogonadism Drug Trial Results Dec 01 2015
Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene Dec 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK